ArticleScientific reports2026
Application of treatment response assessment maps (TRAMs), based on delayed-contrast MRI for radiomic characterization of breast lesions.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Dynamic contrast-enhanced (DCE) breast MRI is a highly sensitive modality for detecting breast cancer, but its limited specificity often leads to false-positive findings and unnecessary biopsies. Radiomics offers a quantitative approach to improve lesion characterization by capturing tumor-related image-based features. In this study, we explored the application of treatment response assessment maps (TRAMs), a technique based on delayed-contrast MRI originally developed for neuro-oncology, to breast imaging. TRAMs are sensitive to late contrast clearance dynamics influenced by vascular and tissue microenvironment properties. By capturing differences in permeability and contrast retention, TRAMs may enable improved differentiation between malignant tumors and abnormal non-tumor or benign tissues, thus enhancing diagnostic precision in breast MRI. Radiomic features were extracted from post-contrast DCE-MRI phases using fat-suppressed T1-weighted MR images (T1-MRI), capturing the dynamic enhancement patterns of 243 breast lesions. TRAMs were generated by subtracting delayed post-contrast images from early post-contrast images (after image pre-processing), and corresponding TRAMs-based radiomic features were calculated. Various machine learning classifiers were trained to differentiate between malignant and benign lesions. The diagnostic performances were evaluated using area under the curve (AUC), sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and accuracy, with 95% confidence intervals. TRAMs-based radiomic models yielded diagnostic performance comparable to conventional T1-MRI models across evaluated metrics. While T1-MRI models achieved AUCs between 0.79 and 0.85, several TRAMs feature combinations reached AUC point estimates of 0.87. A univariate model using the TRAMs feature BlueClustV (representing the volume of the largest cluster of pixels showing contrast clearance at the delayed time point) alone achieved an AUC of 0.86, with balanced sensitivity (0.82) and specificity (0.85), demonstrating high diagnostic value using a single interpretable feature. These results were further supported by competitive PPV, NPV, and accuracy values. ROC analysis demonstrated that TRAMs models maintained favorable sensitivity-specificity tradeoffs, with the univariate BlueClustV feature showing the most balanced curve, emphasizing its diagnostic utility in distinguishing malignant from benign lesions. In summary, TRAMs-based classifiers provide complementary physiological information to standard imaging, suggesting their potential to reduce benign biopsies and aid decision making in breast cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.